Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Fineline Cube Mar 23, 2026
Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Fineline Cube Mar 23, 2026
Company Deals Drug

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Fineline Cube Mar 23, 2026
Company Deals

Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36

Fineline Cube Mar 20, 2026
Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026
Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices

Fineline Cube Mar 23, 2026
Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Fineline Cube Mar 23, 2026
Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Fineline Cube Mar 23, 2026
Company Deals

Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion

Fineline Cube Oct 18, 2022

Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...

Company Drug

CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute

Fineline Cube Oct 18, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...

Company Drug

Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients

Fineline Cube Oct 18, 2022

China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...

Company Drug

Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas

Fineline Cube Oct 18, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...

Company Deals

PureID Medical Technology Secures RMB 100M Series B Funding

Fineline Cube Oct 18, 2022

PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...

Company Drug

Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results

Fineline Cube Oct 18, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...

Company Drug

Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma

Fineline Cube Oct 18, 2022

China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...

Company Deals

Salus Biomed Raises Over RMB 100M in Pre-Series A Financing

Fineline Cube Oct 18, 2022

Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...

Company Drug

Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use

Fineline Cube Oct 18, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...

Company Drug

ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE

Fineline Cube Oct 18, 2022

The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen...

Company Drug

Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China

Fineline Cube Oct 18, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...

Company Deals

Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform

Fineline Cube Oct 17, 2022

China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...

Company Drug

Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer

Fineline Cube Oct 17, 2022

China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...

Company Drug

Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL

Fineline Cube Oct 17, 2022

China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...

Company Drug

Genor Biopharma Initiates First Patient Dosing for GB263T in China

Fineline Cube Oct 17, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...

Company Drug

Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study

Fineline Cube Oct 17, 2022

China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...

Company Drug

Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity

Fineline Cube Oct 17, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...

Company Deals

Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma

Fineline Cube Oct 17, 2022

China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...

Policy / Regulatory

NHSA Completes Expert Review for NRDL Price Negotiation Process

Fineline Cube Oct 17, 2022

The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval

Fineline Cube Oct 17, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...

Posts pagination

1 … 586 587 588 … 638

Recent updates

  • Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
  • Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China
  • Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
  • Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic
  • Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.